Investigational Drug Information for Sapanisertib
✉ Email this page to a colleague
What is the development status for investigational drug Sapanisertib?
Sapanisertib is an investigational drug.
There have been 24 clinical trials for Sapanisertib.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 28th 2016.
The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc., and M.D. Anderson Cancer Center.
Summary for Sapanisertib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 451 |
| WIPO Patent Applications | 283 |
| Japanese Patent Applications | 82 |
| Clinical Trial Progress | Phase 2 (2016-07-28) |
| Vendors | 83 |
Recent Clinical Trials for Sapanisertib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer | Calithera Biosciences, Inc | Phase 2 |
| Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study | M.D. Anderson Cancer Center | Phase 1/Phase 2 |
Clinical Trial Summary for Sapanisertib
Top disease conditions for Sapanisertib
Top clinical trial sponsors for Sapanisertib
US Patents for Sapanisertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
